Unknown

Dataset Information

0

Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial.


ABSTRACT: INTRODUCTION:Anticoagulation therapy in portal vein thrombosis (PVT) in patients with cirrhosis is still a matter of debate. Therefore, the aim of this work was to evaluate the efficacy and safety of nadroparin calcium-warfarin sequential (NWS) anticoagulation therapy in cirrhotic patients and to find an optimal anticoagulation strategy. METHODS:Consecutive cirrhotic patients with PVT who have not received anticoagulation therapy were randomly divided into the NWS therapy group (1-month nadroparin calcium by subcutaneous injection followed by 5-month warfarin by oral administration) and control group (no anticoagulation therapy). Overall recanalization rate of PVT and risks of bleeding were evaluated at the sixth month. RESULTS:Among 64 patients, complete or partial recanalization of PVT was observed in 20/32 NSW therapy group patients vs 11/32 control group patients (62.5% vs 34.4%, P = 0.024), with no statistically significant difference in bleeding rate. Child-Pugh score (P = 0.023), D-dimer < 2.00 ?g/mL (P = 0.020), and NWS anticoagulation therapy (P = 0.004) were predictors associated with the recanalization. NWS anticoagulation therapy (P = 0.008) was an independent predicting factor of recanalization. In the NWS therapy group, the Child-Pugh score (P = 0.007) and albumin level (P = 0.004) were improved in the sixth month. DISCUSSION:NWS anticoagulation therapy was effective and safe in PVT patients with cirrhosis and could increase the level of albumin. NWS therapy is safe and easily accepted.

SUBMITTER: Zhou T 

PROVIDER: S-EPMC7455225 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7782107 | BioStudies
2012-01-01 | S-EPMC3560706 | BioStudies
2020-01-01 | S-EPMC7555202 | BioStudies
2018-01-01 | S-EPMC6092393 | BioStudies
2013-01-01 | S-EPMC3710980 | BioStudies
2019-01-01 | S-EPMC6609842 | BioStudies
1000-01-01 | S-EPMC4415192 | BioStudies
2019-01-01 | S-EPMC7649874 | BioStudies
2018-01-01 | S-EPMC6714657 | BioStudies
2020-01-01 | S-EPMC7566862 | BioStudies